Covid Vaccinations

Off Topic Messages

Moderators: FECC-Moderator, Moderator5, Moderator3, Site Mechanic

User avatar

Topic author
ForeverElvis
Posts: 3184
Registered for: 18 years
Has thanked: 657 times
Been thanked: 1299 times

Covid Vaccinations

Post by ForeverElvis »

My Canadian Province announced a detailed vaccination plan the other day.

————————
B.C. reveals age-based plan to vaccinate general public by September

https://www.cbc.ca/news/canada/british-columbia/covid-19-bc-vaccine-plan-1.5883588
————————

I’m curious to know - where you live has an organized, detailed plan been announced/started?
Last edited by ForeverElvis on Sat Jan 23, 2021 11:59 pm, edited 1 time in total.
Always Elvis
Anthony
User avatar

keninlincs
Posts: 14020
Registered for: 12 years 9 months
Location: East Coast
Mood:
Has thanked: 2305 times
Been thanked: 2463 times
Age: 56

Re: Covid Vaccinations

Post by keninlincs »

Mine is scheduled for Feb as i am classed as clinically vulnerable.
-instagram kenh1964
User avatar

JohanD
Posts: 1425
Registered for: 18 years
Location: Belgium
Has thanked: 256 times
Been thanked: 466 times

Re: Covid Vaccinations

Post by JohanD »

Here (In Belgium) there was a strategy that everyone should/could be vaccinated by this summer.
However, Pfizer and AstraZeneca already has problems with the production by now, and can only deliver half of their products for the moment..... when they promised otherwise....
JohanD
____________
And i'm never gonna cease my wandering...
User avatar

MaryAnn
Posts: 1716
Registered for: 9 years 7 months
Location: St. Louis, Missouri U.S.A.
Has thanked: 984 times
Been thanked: 1109 times

Re: Covid Vaccinations

Post by MaryAnn »

My state, Missouri, is “Dead Last I Vaccinations.” :roll: Attached is the front page of today’s St. Louis Post Dispatch.
You do not have the required permissions to view the files attached to this post.
User avatar

Topic author
ForeverElvis
Posts: 3184
Registered for: 18 years
Has thanked: 657 times
Been thanked: 1299 times

Covid Vaccinations

Post by ForeverElvis »

MaryAnn wrote:My state, Missouri, is “Dead Last I Vaccinations.” :roll: Attached is the front page of today’s St. Louis Post Dispatch.
Very troubling.

I sincerely hope Biden and his Administration can get a state-run nationwide vac program running soon.

Unfortunately, the manufacturer slow down in Belgium will affect us all in the coming weeks.

All the best from Canada Mary-Ann!
Always Elvis
Anthony
User avatar

Walter Hale 4
Posts: 10202
Registered for: 15 years
Has thanked: 2655 times
Been thanked: 1218 times

Re: Covid Vaccinations

Post by Walter Hale 4 »

The AstraZeneca vaccine has finally arrived here but only in South Australia at this time. Hopefully three months away from winter season here, majority of folks will receive their jabs by then -

AstraZeneca COVID-19 vaccination

Australia's rollout of the Oxford-AstraZeneca COVID-19 vaccine will begin on Friday, with the first doses to be administered in South Australia.

Key points:

The AstraZeneca jab is the second vaccine to be given the green light in Australia
Frontline health staff in Murray Bridge will receive the first doses
About 90 staff members are expected to receive the vaccine tomorrow

Prime Minister Scott Morrison said 300,000 doses of the vaccine, which arrived in Sydney on Sunday, have now been "batch-tested" and approved for use.
AstraZeneca is the second COVID vaccine to be given the green light in Australia, after the Pfizer vaccine.

Mr Morrison said the first overseas-manufactured doses of the jab would be followed by 50 million doses made in Melbourne.
User avatar

Walter Hale 4
Posts: 10202
Registered for: 15 years
Has thanked: 2655 times
Been thanked: 1218 times

Re: Covid Vaccinations

Post by Walter Hale 4 »

EU agency finds AstraZeneca vaccine can cause rare blood clots, as UK advises other shots for under-30s

By Angela Dewan and Sharon Braithwaite, CNN

European drug regulators have confirmed a link between the Oxford-AstraZeneca Covid-19 shot and rare blood clots, as UK authorities recommended that people under 30 should take alternative vaccines.
The European Medicines Agency (EMA) said Wednesday that a particular combination of unusual blood clots with low blood platelet counts should be listed as a side effect of the vaccine, but stopped short of recommending its use be limited. The benefits of the shot outweigh the risks and Covid-19 is a "very serious disease," it added.
UK regulators took a more cautious approach, saying healthy adults under 30 should be offered other vaccines. Officials described the move as a "course correction" that would not derail the country's rapid inoculation program.

The findings could have enormous implications for developing and middle-income countries, many of which are accessing the AstraZeneca shot through Covax, a vaccine-sharing scheme.

EMA officials said they looked at 18 deaths in their analysis. These fatalities were reported in 62 cases of clotting in the sinuses that drain blood from the brain, and 24 cases of clotting in the abdomen. The cases were reported in an EU safety database from European countries, including the UK, where around 25 million people in total had received the AstraZeneca vaccine.
"First of all, I want to start by stating that our safety committee (the Pharmacovigilance and Risk Assessment Committee or PRAC) ... has confirmed that the benefits of the AstraZeneca vaccine in preventing Covid-19 overall outweigh the risks of side effects," EMA Executive Director Emer Cooke told a press conference.
PRAC chair Sabine Straus reiterated the cases of severe clotting with low blood platelet counts were extremely rare but conceded, when challenged by journalists, that EMA did not have the data to understand the extent to which benefits might still outweigh risks for particular groups, by age or sex, for example.
"At the moment that's something that's very difficult to answer because the clinical trials ... we do not have all the age stratified data available," said Straus, adding that the agency planned to obtain that data and undertake further analysis.
Cooke said there was no clear risk profile found when the safety committee looked at the age and sex of people reporting these rare adverse reactions, even though a statement published by EMA earlier made clear most of the cases reported "occurred in women under 60 years of age within 2 weeks of vaccination."
EMA's statement called on healthcare workers and people receiving the vaccine "to remain aware of the possibility of very rare cases of blood clots combined with low levels of blood platelets occurring within 2 weeks of vaccination."
UK authorities also concluded the benefits outweighed the risks in most age groups, but presented data that showed the benefits to people under 30 only slightly outweighed the risks in scenarios where exposure to the virus is limited. Those who had already received the first AstraZeneca shot, however, should be offered the second, they said.
EMA's findings and the UK's new advice also follow a move in Germany, which last week suspended the use of the AstraZeneca vaccine in people under 60 years old after 31 reports of CVST. Twenty-nine of the 31 were women aged 20 to 63, and nine of the patients died, according to a Reuters report citing the country's medicines regulator.
After reviewing the data from EMA and the UK, the World Health Organization said in a statement Wednesday that "based on current information, a causal relationship between the vaccine and the occurrence of blood clots with low platelets is considered plausible but is not confirmed. Specialised studies are needed to fully understand the potential relationship between vaccination and possible risk factors."
What does the data say?
The UK's deputy chief medical officer, Jonathan Van-Tam, presented charts Wednesday showing the balance of risks and benefits for each age group in getting the AstraZeneca vaccine in the UK.
It showed the vaccine offered only slightly higher benefits than risks for people under 30, in scenarios where people are not very exposed -- such as those working from home. The analysis considered the likelihood of being admitted to intensive care as its main metric.
'One mistake after the other.' How AstraZeneca went from pandemic hero to villain
'One mistake after the other.' How AstraZeneca went from pandemic hero to villain
People who are around the limit of the age recommendation should make "their own decision" about whether to accept an AstraZeneca vaccine, said the chair of the UK's Joint Committee on Vaccination and Immunization, Wei Shen Lim.
"For somebody who's 31 and 32, I think they have to make their own decision as to what they want to do about vaccination," he said. "We would still say that the balance is in favor of being vaccinated because of the risks from Covid-19 and the protection that the vaccine offers."
Oxford University said Wednesday that the "the identification of rare cases of blood clots, which might be associated with the vaccine, shows that the safety system works."
"Safety has been our priority throughout the development of the vaccine at University of Oxford in 2020, and we are reassured to see that safety monitoring continues under the close scrutiny of regulators and public health authorities as the vaccine is rolled out around the world," Andrew Pollard, Professor of Paediatric Infection and Immunity, said in a statement.
AstraZeneca said Wednesday that it was "collaborating with regulators" to update its product information regarding possible side effects following the announcements by British and European regulators.
"Updates to the UK and EU labels for the vaccine have been requested by the regulators. Neither agency identified any risk factors, such as age or gender, or a definite cause for these extremely rare events. However, they came to the view that these events have a possible link to the vaccine and requested they be listed as an extremely rare potential side effect," it said.
"Overall, both of these reviews reaffirmed the vaccine offers a high-level of protection against all severities of COVID-19 and that these benefits continue to far outweigh the risks," the statement added.

Safety concerns around the vaccine is the latest headache for drug company AstraZeneca, which has been at the center of a public war of words between the European Union and UK as it has fallen tens of millions of doses short on its delivery targets to the EU, while appearing to make good on its supplies to the UK.
The company has also come under the scrutiny of drug regulators, including the US Food and Drug Authority, for presenting outdated clinical trial data and, earlier, for mixing data from separate trials that were conducted differently.

CNN's Richard Allen Greene, Schams Elwazer, Ivana Kottasová, Chloe Adams and Zahid Mahmood contributed to this report.

https://edition.cnn.com/2021/04/07/health/astrazeneca-coronavirus-vaccine-europe-uk-ema-intl/index.html
User avatar

pmp
Posts: 3538
Registered for: 1 year 11 months
Has thanked: 502 times
Been thanked: 2780 times

Re: Covid Vaccinations

Post by pmp »

Walter Hale 4 wrote:
Thu Apr 08, 2021 12:49 pm
EU agency finds AstraZeneca vaccine can cause rare blood clots, as UK advises other shots for under-30s

By Angela Dewan and Sharon Braithwaite, CNN

European drug regulators have confirmed a link between the Oxford-AstraZeneca Covid-19 shot and rare blood clots, as UK authorities recommended that people under 30 should take alternative vaccines.
The European Medicines Agency (EMA) said Wednesday that a particular combination of unusual blood clots with low blood platelet counts should be listed as a side effect of the vaccine, but stopped short of recommending its use be limited. The benefits of the shot outweigh the risks and Covid-19 is a "very serious disease," it added.
UK regulators took a more cautious approach, saying healthy adults under 30 should be offered other vaccines. Officials described the move as a "course correction" that would not derail the country's rapid inoculation program.

The findings could have enormous implications for developing and middle-income countries, many of which are accessing the AstraZeneca shot through Covax, a vaccine-sharing scheme.

EMA officials said they looked at 18 deaths in their analysis. These fatalities were reported in 62 cases of clotting in the sinuses that drain blood from the brain, and 24 cases of clotting in the abdomen. The cases were reported in an EU safety database from European countries, including the UK, where around 25 million people in total had received the AstraZeneca vaccine.
"First of all, I want to start by stating that our safety committee (the Pharmacovigilance and Risk Assessment Committee or PRAC) ... has confirmed that the benefits of the AstraZeneca vaccine in preventing Covid-19 overall outweigh the risks of side effects," EMA Executive Director Emer Cooke told a press conference.
PRAC chair Sabine Straus reiterated the cases of severe clotting with low blood platelet counts were extremely rare but conceded, when challenged by journalists, that EMA did not have the data to understand the extent to which benefits might still outweigh risks for particular groups, by age or sex, for example.
"At the moment that's something that's very difficult to answer because the clinical trials ... we do not have all the age stratified data available," said Straus, adding that the agency planned to obtain that data and undertake further analysis.
Cooke said there was no clear risk profile found when the safety committee looked at the age and sex of people reporting these rare adverse reactions, even though a statement published by EMA earlier made clear most of the cases reported "occurred in women under 60 years of age within 2 weeks of vaccination."
EMA's statement called on healthcare workers and people receiving the vaccine "to remain aware of the possibility of very rare cases of blood clots combined with low levels of blood platelets occurring within 2 weeks of vaccination."
UK authorities also concluded the benefits outweighed the risks in most age groups, but presented data that showed the benefits to people under 30 only slightly outweighed the risks in scenarios where exposure to the virus is limited. Those who had already received the first AstraZeneca shot, however, should be offered the second, they said.
EMA's findings and the UK's new advice also follow a move in Germany, which last week suspended the use of the AstraZeneca vaccine in people under 60 years old after 31 reports of CVST. Twenty-nine of the 31 were women aged 20 to 63, and nine of the patients died, according to a Reuters report citing the country's medicines regulator.
After reviewing the data from EMA and the UK, the World Health Organization said in a statement Wednesday that "based on current information, a causal relationship between the vaccine and the occurrence of blood clots with low platelets is considered plausible but is not confirmed. Specialised studies are needed to fully understand the potential relationship between vaccination and possible risk factors."
What does the data say?
The UK's deputy chief medical officer, Jonathan Van-Tam, presented charts Wednesday showing the balance of risks and benefits for each age group in getting the AstraZeneca vaccine in the UK.
It showed the vaccine offered only slightly higher benefits than risks for people under 30, in scenarios where people are not very exposed -- such as those working from home. The analysis considered the likelihood of being admitted to intensive care as its main metric.
'One mistake after the other.' How AstraZeneca went from pandemic hero to villain
'One mistake after the other.' How AstraZeneca went from pandemic hero to villain
People who are around the limit of the age recommendation should make "their own decision" about whether to accept an AstraZeneca vaccine, said the chair of the UK's Joint Committee on Vaccination and Immunization, Wei Shen Lim.
"For somebody who's 31 and 32, I think they have to make their own decision as to what they want to do about vaccination," he said. "We would still say that the balance is in favor of being vaccinated because of the risks from Covid-19 and the protection that the vaccine offers."
Oxford University said Wednesday that the "the identification of rare cases of blood clots, which might be associated with the vaccine, shows that the safety system works."
"Safety has been our priority throughout the development of the vaccine at University of Oxford in 2020, and we are reassured to see that safety monitoring continues under the close scrutiny of regulators and public health authorities as the vaccine is rolled out around the world," Andrew Pollard, Professor of Paediatric Infection and Immunity, said in a statement.
AstraZeneca said Wednesday that it was "collaborating with regulators" to update its product information regarding possible side effects following the announcements by British and European regulators.
"Updates to the UK and EU labels for the vaccine have been requested by the regulators. Neither agency identified any risk factors, such as age or gender, or a definite cause for these extremely rare events. However, they came to the view that these events have a possible link to the vaccine and requested they be listed as an extremely rare potential side effect," it said.
"Overall, both of these reviews reaffirmed the vaccine offers a high-level of protection against all severities of COVID-19 and that these benefits continue to far outweigh the risks," the statement added.

Safety concerns around the vaccine is the latest headache for drug company AstraZeneca, which has been at the center of a public war of words between the European Union and UK as it has fallen tens of millions of doses short on its delivery targets to the EU, while appearing to make good on its supplies to the UK.
The company has also come under the scrutiny of drug regulators, including the US Food and Drug Authority, for presenting outdated clinical trial data and, earlier, for mixing data from separate trials that were conducted differently.

CNN's Richard Allen Greene, Schams Elwazer, Ivana Kottasová, Chloe Adams and Zahid Mahmood contributed to this report.

https://edition.cnn.com/2021/04/07/health/astrazeneca-coronavirus-vaccine-europe-uk-ema-intl/index.html
It has to be remembered, though, just how rare this is.

We are at a stage where every 1 in 524 people in the UK have died within 28 days of having tested positive for the virus.*
Around 1 in 1.3 million people have died after having the vaccine.

Which chance would people rather take?

*That's not 1 in 524 with the virus. That's 1 in 524 of everybody.
Accused of being "a nerd in his 20s." I wish.
User avatar

YDKM
Posts: 11296
Registered for: 18 years
Location: Nothingville, Sydney, N.S.W.Australia
Has thanked: 3733 times
Been thanked: 1377 times
Age: 60

Re: Covid Vaccinations

Post by YDKM »

yes and in Australia its roll out is awfully poor.
Bruce Jackson Born June 3rd 1949- Died January 29th 2011 Elvis's Sound Engineer from 1971-1977.
You Don't Know Me!